Among patients with type 2 diabetes, the use of GLP-1 receptor agonists was associated with a lower risk of major adverse ...
Net loss for the fourth quarter of 2024 totaled $36.5M with non-cash share-based compensation expense of $5.8 M compared to $24.5M for the ...
ACCESS and ACCESS II studies fully enrolled; topline data from both studies anticipated by year-end 2025Oral small ...
The American College of Cardiology and American Heart Association issued updated practice guidelines for the management of ...
New resource highlights critical role of lifestyle interventions in maximizing weight loss success and addressing limitations of GLP-1 therapiesMONTREAL, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Ideal ...
5h
The WEGOVY market has experienced significant growth, driven by rising obesity rates and increasing demand for effective weight-loss treatments. Novo Nordisk's blockbuster drug has seen strong ...
New diabetes medications are pressuring Medicare Part D financially as they drive up prescription drug costs amid rising ...
SALT LAKE CITY, UTAH / ACCESS Newswire / February 27, 2025 / CenExel is pleased to announce its partnership with Metsera, Inc., a clinical-stage biopharmaceutical company dedicated to advancing treatm ...
While Kallyope’s drugs are mechanistically unique, the biotech is competing in a crowded space, with other therapies that ...
Kallyope has slipped out results from a phase 2 trial of its obesity candidates, linking the combination of the two oral ...
For older adults with type 2 diabetes, use of GLP-1 RAs is associated with a modestly lower risk for depression compared with DPP-4i use.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback